Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 2Radiation Injuries 1Peripheral Nervous System Diseases 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Gangliosidosis, GM1 1Gangliosidoses 1Colorectal Neoplasms 1Cognitive Dysfunction 1Brain Neoplasms 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × G(M1) Ganglioside × Clear all
NCT02093910 2014-11-19

Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy

Sun Yat-sen University

Phase 2 Unknown
100 enrolled
Plasma cell

Multiple Myeloma, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡